SUBSCRIBE
SUBSCRIBE
Dan Samorodnitsky

Dan Samorodnitsky

News Editor

Dan Samorodnitsky is the news editor at BioSpace. He has a decade of experience covering biotech, genetics and medicine. Before coming to BioSpace he was an editor at Drug Discovery News and Massive Science, and his writing has appeared in outlets such as Quanta, STAT, GROW and many others. He is based in Minneapolis. You can reach him at dan.samorodnitsky@biospace.com.

Adult people customers group in casual clothes standing in long line queue
Gene therapy
Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp
Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple in 2026, as patient access to the sickle cell disease and beta thalassemia gene therapy grows.
February 13, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
FDA
FDA’s Prasad Weathers Personal Controversy, Internal Strife Amid Moderna Imbroglio
Vinay Prasad, the FDA’s Center for Biologics Evaluation and Research head, is accused of interpersonal impropriety as pushback builds against his decision to reject Moderna’s influenza vaccine candidate.
February 12, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Contemporary artwork. Businessman jumping over bear trap with briefcase and documents. Concept of business risk, hidden financial dangers, legal pitfalls, investment fraud and consumer protection.
Vaccines
Flu Vaccine Rejection Imperils Moderna’s Breakeven Plans
Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. That plan is now out the window after the FDA refused to even look at the application.
February 12, 2026
 · 
4 min read
 · 
Dan Samorodnitsky
Collage with colorful casino chips cards dices representing online gambling poker betting e-gaming entertainment.
Rare diseases
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work?
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
February 12, 2026
 · 
4 min read
 · 
Dan Samorodnitsky
3d rendering, Business e-mail. Open envelope with cross mark on sheet of paper. Rejected contract, document cancelled, not verified.
Editorial
All the Ways Moderna’s Flu Vaccine Rejection Letter Shocked Us
The FDA issued a rare Refusal-to-File letter to Moderna over its mRNA-based influenza vaccine application, in an unusual move that sent the biotech’s shares tumbling.
February 11, 2026
 · 
4 min read
 · 
Dan Samorodnitsky
Podcast
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
A lawsuit and FDA warning ensued after Hims & Hers launched a compounded version of Novo Nordisk’s new obesity pill, more Big Pharma report earnings—including from weight loss rivals Novo and Eli Lilly—and the gene therapy space sees another rejection.
February 11, 2026
 · 
1 min read
 · 
Jef Akst
Creative picture image collage banner of guy worker jump from financial charts determined company success.
Immunology and inflammation
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical trial.
February 10, 2026
 · 
1 min read
 · 
Dan Samorodnitsky
Creativity and new ideas in business. Art collage.
Mergers & acquisitions
Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune
The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical testing, is focused on B cell–driven autoimmune diseases.
February 9, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Digital compass. Business strategic explorer, Vision crisis, Mission path, Agency creative, Digital strategy, Market decision, Achievement strategy, Financial stock, Company vision concepts
Policy
FDA Policy Tracker 2026: Priority Vouchers Questioned, PRVs Return
A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns surface about the politicization of the agency.
February 9, 2026
 · 
5 min read
 · 
Heather McKenzie
Graphic drawing white background
Psychedelics
AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing
Sales of Johnson & Johnson’s esketamine-based nasal spray jumped in the fourth quarter last year, priming the pump for a suite of other pharmas, including AbbVie, champing at the bit with their own psychedelics.
February 6, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Donald Trump signing an executive order
Drug pricing
TrumpRx Website Set To Launch Thursday Evening After Delay
The administration’s direct-to-consumer pharmaceutical sales platform will offer products from Eli Lilly, Pfizer, Novo Nordisk, Amgen and more at a discount, though the impact of such pricing remains to be seen.
February 5, 2026
 · 
1 min read
 · 
Dan Samorodnitsky
Pictured: Bristol Myers Squibb office in California
Earnings
BMS Beats Again Despite Eliquis and Cobenfy Disappointments
Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy continues to struggle with uptake.
February 5, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Trend artwork 3D photo collage sketch image of young sad stressed lady with headache burnout deadline overloaded tired work in office.
Duchenne muscular dystrophy
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up
After a series of deaths in patients taking Sarepta Therapeutics’ gene therapies, doubt has crept into investor sentiments around the long-time Wall Street darling, and patients may soon begin looking elsewhere.
February 5, 2026
 · 
5 min read
 · 
Dan Samorodnitsky
South San Francisco, CA, USA - Feb 23, 2024: Exterior view of AbbVie's research facility in South San Francisco. AbbVie is an American pharmaceutical company headquartered in North Chicago, Illinois.
Earnings
AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas
On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.
February 4, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed execs for more details; Merck and Roche also released Q4 and full year earnings, with Eli Lilly, Novo Nordisk and others reporting Wednesday; REGENXBIO hits a regulatory snag ahead of its upcoming PDUFA; more.
February 4, 2026
 · 
1 min read
 · 
Heather McKenzie
Load More